Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-05-20 DOI:10.1080/14737167.2024.2353727

Aziz Rezapour, Hanie Gholampour, Mohammad Barzegar, Kamran Irandoust, Somayeh Afshari, Jalal Arabloo, Razieh Mahmoodi, Ali Sarabi Asiabar, Pezhman Atefimanesh, Mohammad Hossein Ghafoori

{"title":"Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review.","authors":"Aziz Rezapour, Hanie Gholampour, Mohammad Barzegar, Kamran Irandoust, Somayeh Afshari, Jalal Arabloo, Razieh Mahmoodi, Ali Sarabi Asiabar, Pezhman Atefimanesh, Mohammad Hossein Ghafoori","doi":"10.1080/14737167.2024.2353727","DOIUrl":null,"url":null,"abstract":"Introduction: This systematic review study investigated the cost-effectiveness of stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) for treatment of various types of cancers.Methods: PubMed, Scopus, and Web of Science were searched from 30 December 1990 to 1 January 2023. The entered studies were screened in accordance with the inclusion criteria. The inclusion criteria encompassed all types of economic evaluation studies that investigated SRT/SRS technologies in the treatment of various cancers.Results: A total of 47 articles were included in the review. The findings suggest that the use of Linear accelerator technology for the treatment of lung cancer (8 out of 12 studies) and prostate cancer (4 out of 5 studies) was a cost-effective strategy. Linear accelerator was found to be cost-effective in the treatment of liver metastases and liver cancer (2 out of 5 studies). All of the included studies that used Gamma Knife technology in brain metastases reported Gamma-Knife was a cost-effective treatment. Furthermore, in the treatment of prostate and liver cancer, proton therapy was identified as a cost-effective option than other treatments.Conclusions: This study confirms that SRT/SRS is a cost-effective procedure for the treatment of various types of cancers. Therefore, it is recommended to use SRT/SRS technology for optimal use of resources.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2353727","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This systematic review study investigated the cost-effectiveness of stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) for treatment of various types of cancers.

Methods: PubMed, Scopus, and Web of Science were searched from 30 December 1990 to 1 January 2023. The entered studies were screened in accordance with the inclusion criteria. The inclusion criteria encompassed all types of economic evaluation studies that investigated SRT/SRS technologies in the treatment of various cancers.

Results: A total of 47 articles were included in the review. The findings suggest that the use of Linear accelerator technology for the treatment of lung cancer (8 out of 12 studies) and prostate cancer (4 out of 5 studies) was a cost-effective strategy. Linear accelerator was found to be cost-effective in the treatment of liver metastases and liver cancer (2 out of 5 studies). All of the included studies that used Gamma Knife technology in brain metastases reported Gamma-Knife was a cost-effective treatment. Furthermore, in the treatment of prostate and liver cancer, proton therapy was identified as a cost-effective option than other treatments.

Conclusions: This study confirms that SRT/SRS is a cost-effective procedure for the treatment of various types of cancers. Therefore, it is recommended to use SRT/SRS technology for optimal use of resources.

查看原文本刊更多论文

立体定向放射治疗和立体定向放射外科技术在癌症治疗中的经济评估：系统性综述。

简介：本系统综述研究调查了立体定向放射治疗（SRT）和立体定向放射手术（SRS）治疗各种癌症的成本效益：本系统综述研究调查了立体定向放射治疗（SRT）和立体定向放射手术（SRS）治疗各类癌症的成本效益：方法：检索了 1990 年 12 月 30 日至 2023 年 1 月 1 日期间的 PubMed、Scopus 和 Web of Science。根据纳入标准对输入的研究进行了筛选。纳入标准包括调查 SRT/SRS 技术治疗各种癌症的各类经济评估研究：综述共纳入 47 篇文章。研究结果表明，使用直线加速器技术治疗肺癌（12 项研究中的 8 项）和前列腺癌（5 项研究中的 4 项）是一种具有成本效益的策略。直线加速器治疗肝转移和肝癌（5 项研究中的 2 项）具有成本效益。所有纳入的使用伽玛刀技术治疗脑转移瘤的研究均报告伽玛刀是一种具有成本效益的治疗方法。此外，在前列腺癌和肝癌的治疗中，质子疗法被认为是比其他疗法更具成本效益的选择：这项研究证实，SRT/SRS 是治疗各种癌症的一种经济有效的方法。因此，建议使用 SRT/SRS 技术以优化资源利用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.